

Financial news for ANAC dated on 2016-12-28: A Preview Of January PDUFA Dates

Financial news for ANAC dated on 2016-06-13: Watch These 5 Huge Call Purchases In Monday Trade

Financial news for ANAC dated on 2016-06-10: Option Alert: ANAC Jan17 110 Calls: 500 @ Above Ask! \$0.40: 509 traded vs 1860 OI: \$99.22 Ref

Financial news for ANAC dated on 2016-06-09: Option Alert: ANAC Jan17 110 Calls: 500 @ Above Ask! \$0.50: 500 traded vs 2860 OI: \$99.23 Ref

Financial news for ANAC dated on 2016-05-31: Option Alert: ANAC Aug16 100 Calls: 1500 @ ASK \$0.70: 1911 traded vs 33k OI: \$99.27 Ref

Financial news for ANAC dated on 2016-05-26: Anacor Says Citi Reps Conveyed That Company Board Was Not Prepared To Accept May 6th Pfizer Proposal Because Company Received Third Party Offer; Pfizer Then Proposed "Best And Final" Offer Of \$99.25/Share Cash May 16th

Financial news for ANAC dated on 2016-05-26: UPDATE: Filing Out Regarding Pfizer Tender Offer

Financial news for ANAC dated on 2016-05-26: Anacor Pharmaceuticals Spikes to High of \$99.53

Financial news for ANAC dated on 2016-05-18: Benzinga's Top Downgrades

Financial news for ANAC dated on 2016-05-18: Mizuho Securities Downgrades Anacor Pharmaceuticals to Neutral

Financial news for ANAC dated on 2016-05-17: Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma

Financial news for ANAC dated on 2016-05-17: A Look At All Of Pfizer's Acquisitions Over The Past 2 Years

Financial news for ANAC dated on 2016-05-17: Bull And Bear Takeaways From Pfizer's \$5.2 Billion Deal

Financial news for ANAC dated on 2016-05-16: Benzinga's M&A Chatter for Monday May 16, 2016

Financial news for ANAC dated on 2016-05-16: Option Alert: SWEEP (BUY) - ANAC Aug \$100 Put - 600 @ 2.801 in 7 orders. 605 traded. OI: 0

Financial news for ANAC dated on 2016-05-16: Mid-Afternoon Market Update: Dow Jumps 200 Points; Aduro Biotech Shares Drop Following Announcement of Failed Phase 2b ECLIPSE Trial

Financial news for ANAC dated on 2016-05-16: JMP Cuts Anacor Pharmaceuticals PT From \$173 To \$130, Maintains Market Outperform

Financial news for ANAC dated on 2016-05-16: UPDATE: Anacor Shares Up ~\$1 Over Last Few Mins Following Mid-Day Comments from JMP Analyst

Financial news for ANAC dated on 2016-05-16: Shares of Anacor Spike Higher as Hearing JMP Has Said Expects a Competing \$130/Share Bid from Novartis

Financial news for ANAC dated on 2016-05-16: 8 Biggest Mid-Day Market Gainers

Financial news for ANAC dated on 2016-05-16: Mid-Day Market Update: Nanosphere Jumps Following Luminex Deal; Breitburn Energy Partners Shares Drop

Financial news for ANAC dated on 2016-05-16: Benzinga's Volume Movers

Financial news for ANAC dated on 2016-05-16: Mid-Morning Market Update: Markets Open Higehr; Pfizer To Acquire Anacor Pharmaceuticals For \$5.2B

Financial news for ANAC dated on 2016-05-16: The Market In 5 Minutes: Need A Hand?

Financial news for ANAC dated on 2016-05-16: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for ANAC dated on 2016-05-16: Merger Monday: 6 Deals, Rumors And Bids You Might Have Missed

Financial news for ANAC dated on 2016-05-16: Pfizer To Buy Anacor For \$5.2 Billion

Financial news for ANAC dated on 2016-05-16: Pfizer Acquisition of Anacor Valued at

\$5.2B

Financial news for ANAC dated on 2016-05-16: Pfizer Announces Acquisition of Anacor for \$99.25/Share Cash

Financial news for ANAC dated on 2016-05-10: Anacor Pharma Q1 EPS (\$0.36) vs (\$0.36) est, Revenue \$17.54M vs \$18.67M est

Financial news for ANAC dated on 2016-04-06: Mid-Afternoon Market Update: Crude Oil Up Over 4%; Acuity Brands Shares Surge On Earnings Beat

Financial news for ANAC dated on 2016-04-06: Mid-Day Market Update: U.S. Stocks Rise; Cree Shares Decline On Weak Outlook

Financial news for ANAC dated on 2016-04-01: Anacor Pharmaceuticals Prices Offering of \$250M of 2.00% Convertible Senior Notes Due 2023

Financial news for ANAC dated on 2016-03-22: Anacor Pharma Reports FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for Treatment of Mild-to-Moderate Atopic Dermatitis

Financial news for ANAC dated on 2016-03-18: Mid-Morning Market Update: Markets Open Higher; Tiffany Q4 Profit Beats Views

Financial news for ANAC dated on 2016-03-11: Benzinga's Top Initiations

Financial news for ANAC dated on 2016-03-11: Mizuho Securities Initiates Coverage on Anacor Pharmaceuticals at Buy, Announces \$103.00 PT

Financial news for ANAC dated on 2016-02-24: Anacor Pharmaceuticals Says Intends to Vigorously Defend Kerydin Orange Book Patents in IPR Proceedings -8K

Financial news for ANAC dated on 2016-02-23: A Visual Look At Valeant's Dark Monday

Financial news for ANAC dated on 2016-02-22: UPDATE: Jefferies Sees No Concern ANAC May Need To Issue Equity To Raise More Cash, Says Co Should Be Cashflow Positive In FY 2016 And Beyond

Financial news for ANAC dated on 2016-02-22: Jefferies' Dave Steinberg Says Jublia Not Substitutable For Kerydin At WBA Pharmacies, Says ANAC Has More Than Sufficient Cash

Financial news for ANAC dated on 2016-02-22: Traders Attributing Move Higher in Anacor to Report CVS Has Restricted Use of Valeant's Jublia, an Assumed Competing Product to Kerydin

Financial news for ANAC dated on 2016-02-22: Anacor Pharmaceuticals Spikes to High of \$78.82 on Volume

Financial news for ANAC dated on 2016-02-19: ANAC Jan17 75.0 Calls: 2000 @ ASK \$19.50: 2000 traded vs 0 OI: Earnings 3/10 \$70.84 Ref

Financial news for ANAC dated on 2016-01-26: Mid-Afternoon Market Update: Crude Oil Climbs 6%; Sprint Shares Gain Following Strong Q3 Earnings

Financial news for ANAC dated on 2016-01-26: Mid-Day Market Update: Dow Surges Over 250 Points; Firstmerit Shares Rise On Acquisition News

Financial news for ANAC dated on 2016-01-07: Anacor Pharmaceuticals Submits New Drug Application to the FDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis

Financial news for ANAC dated on 2015-12-28: Wedbush Offers Weekly Retail Sales Tracker for Recently-Launched Drugs: Anacor's KERYDIN Total Prescriptions Up 15.3% WoW, New Scripts Down 0.8% WoW

Financial news for ANAC dated on 2015-12-14: The Five Best Biotech Analyst Calls Of 2015

Financial news for ANAC dated on 2015-11-03: Anacor Pharma Reports Q3 Loss of \$0.37/Share vs Loss of \$0.28/Share Est., Sales \$24.55M vs \$25.3M Est.

Financial news for ANAC dated on 2015-10-29: Anacor Pharmaceuticals Reports Top-Line Results From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis

Financial news for ANAC dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for ANAC dated on 2015-09-29: Anacor Pharma Reports Presentations of

Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at Two Upcoming Conferences

Financial news for ANAC dated on 2015-08-14: Anacor Pharma 13D Shows Holder GlaxoSmithKline Has 4.9% Stake As Of August 13

Financial news for ANAC dated on 2015-08-06: Anacor Pharmaceuticals Reports Q2 EPS of \$(0.30) vs \$(0.33) Est; Revenue of \$21.34M vs \$18.55M Est

Financial news for ANAC dated on 2015-08-06: Anacor Pharma Reports Q2 GAAP Loss of \$0.30/Share vs Loss of \$0.32/Share Est., Sales \$21.3M vs \$18.8M Est.

Financial news for ANAC dated on 2015-07-21: Stocks Hitting 52-Week Highs

Financial news for ANAC dated on 2015-07-21: Benzinga's Top Upgrades

Financial news for ANAC dated on 2015-07-21: Goldman Sachs Upgrades Anacor Pharmaceuticals to Buy, Raises PT to \$195.00

Financial news for ANAC dated on 2015-07-21: Goldman Sachs Upgrades Anacor Pharma To Buy On 'De-Risked' Story

Financial news for ANAC dated on 2015-07-16: Preliminary Results of Two Phase 3 Pivotal Studies - Report on Anacor Pharmaceuticals, Inc.

Financial news for ANAC dated on 2015-07-13: Anacor Shares Surge To All-Time Highs After Phase 3 Trials Of Eczema Drug

Financial news for ANAC dated on 2015-07-13: Wedbush On Anacor Pharma: Crisaborole Delivers, Reiterate Outperform

Financial news for ANAC dated on 2015-07-13: Monday's Mid-Day Movers: Greece Reaches Deal, Dow Up Triple Digits

Financial news for ANAC dated on 2015-07-13: Wedbush Maintains Outperform on Anacor Pharmaceuticals, Raises PT to \$190.00

Financial news for ANAC dated on 2015-07-13: Mid-Morning Market Update: Markets Open Higher; BorgWarner To Acquire Remy International For \$29.50/Share

Financial news for ANAC dated on 2015-07-13: Benzinga's Volume Movers

Financial news for ANAC dated on 2015-07-13: Morning Market Gainers

Financial news for ANAC dated on 2015-07-13: Benzinga's Top #PreMarket Gainers

Financial news for ANAC dated on 2015-07-13: Anacor Pharmaceuticals Shares Rise 65% Premarket After Announcing Positive Top-Line Results from Atopic Dermatitis Studies

Financial news for ANAC dated on 2015-07-13: UPDATE: Anacor Crisaborole Achieved Statistically Significant Results

Financial news for ANAC dated on 2015-07-13: UPDATE: Anacor Pharma Sees Filing NDA for Crisaborole During 1H'16

Financial news for ANAC dated on 2015-07-13: Anacor Pharma Reports Top-Line Results from Two Phase 3 PIVOTAL Studies of Crisaborole Topical Ointment: Achieved Statistically Significant Results on Primary, Secondary Endpoints

Financial news for ANAC dated on 2015-07-09: Cowen Note Saying 'strong efficacy could support \$2B+ In AN2728 Sales - Sources

Financial news for ANAC dated on 2015-06-01: Anacor Pharmaceutics Appoints Graeme Bell EVP, CFO

Financial news for ANAC dated on 2015-05-29: Who's The Next Big Pharma Acquisition?

Financial news for ANAC dated on 2015-03-13: Morning Market Gainers

Financial news for ANAC dated on 2015-03-12: FXCM, Jamba Lead After-Hours Movers On Thursday

Financial news for ANAC dated on 2015-03-12: Anacor Pharma Reports Q4 EPS \$(0.24) vs. Est. \$(0.61), Rev. \$9.6M vs. Est. \$4.74M

Financial news for ANAC dated on 2015-03-10: Option Alert: Anacor Pharma Aug \$55 Call; 1000 Contract Trade at Ask @\$6.50; Now \$49.58

Financial news for ANAC dated on 2015-01-07: Symbiota Names David Perry President, CEO

Financial news for ANAC dated on 2014-12-17: Goldman Sachs Initiates Coverage on Anacor Pharmaceuticals at Neutral, Announces \$36.00 PT

Financial news for ANAC dated on 2014-10-20: Stocks Hitting 52-Week Highs

Financial news for ANAC dated on 2014-10-08: Anacor Pharma Reports Proposed Offering of \$70M in Convertible Notes

Financial news for ANAC dated on 2014-10-08: Anacor Pharmaceuticals, Inc. Announces Proposed Offering of \$70M Of Convertible Senior Notes Due 2021

Financial news for ANAC dated on 2014-08-07: Anacor Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.58) vs \$(0.63) Est; Revenue of \$2.93M vs \$3.03M Est

Financial news for ANAC dated on 2014-07-21: Benzinga's Volume Movers

Financial news for ANAC dated on 2014-07-21: Anacor Pharmaceuticals And Sandoz Enter Into An Agreement For The Commercialization Of KERYDIN In The United States

Financial news for ANAC dated on 2014-07-08: FDA Has Approved Anacor Pharma's KERYDIN Topical Solution, 5% for Treatment of Onychomycosis of the Toenails

Financial news for ANAC dated on 2014-07-02: 5-Star Biotech Stock Watch: Anacor Pharmaceuticals

Financial news for ANAC dated on 2014-05-07: Anacor Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.51) vs \$(0.39) Est; Revenue of \$4.16M vs \$2.82M Est

Financial news for ANAC dated on 2014-04-21: Jefferies Initiates Coverage on Anacor Pharmaceuticals, Inc. at Buy, Announces \$24.00 PT

Financial news for ANAC dated on 2014-04-03: Mid-Afternoon Market Update: Markets Go Red as Anadarko Rallies on Settlement with US

Financial news for ANAC dated on 2014-04-03: Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split

Financial news for ANAC dated on 2014-03-31: US Stock Futures Up Ahead Of Chicago PMI

Financial news for ANAC dated on 2014-03-31: Anacor Pharmaceuticals Enrolls First Patient in Phase 3 Trial of AN2728 in Mild-to-Moderate Atopic Dermatitis

Financial news for ANAC dated on 2014-03-19: Anacor Pharma Names Paul Berns CEO, Pres

Financial news for ANAC dated on 2014-03-13: Anacor Pharmaceuticals, Inc. Reports Q4 EPS of \$3.01, Inline; Revenue of \$8.49M vs \$2.85M Est

Financial news for ANAC dated on 2014-03-13: Earnings Scheduled For March 13, 2014

Financial news for ANAC dated on 2014-02-27: Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the Treatment of Mild-to-Moderate Atopic Dermatitis With AN2728

Financial news for ANAC dated on 2013-11-07: Anacor Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.41) vs \$(0.39) Est; Revenue of \$3.61M vs \$2.57M Est

Financial news for ANAC dated on 2013-10-28: Shares of Anacor Pharma to Resume Trade at 8:30AM EDT

Financial news for ANAC dated on 2013-10-28: Anacor Pharma Reports Settlement Deal with Valeant, Valeant Will Pay Anacor \$142.5M

Financial news for ANAC dated on 2013-10-28: Anacor Pharma Halted News Pending

Financial news for ANAC dated on 2013-10-21: Anacor Pharmaceuticals Awarded \$13.5M in Research Agreement with Defense Threat Reduction Agency

Financial news for ANAC dated on 2013-10-18: Benzinga's Top Pre-Market Gainers

Financial news for ANAC dated on 2013-10-17: Anacor Pharmaceuticals Announces Award of \$100M in Arbitration with Valeant

Financial news for ANAC dated on 2013-08-22: These Three Speculative Small Caps Are Loved By Insiders and Institutions

Financial news for ANAC dated on 2013-08-15: Top Double Digit Winners and Losers From Wednesday, August 14, 2013

Financial news for ANAC dated on 2013-08-14: Stocks Hitting 52-Week Highs

Financial news for ANAC dated on 2013-08-08: Anacor Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.36) vs \$(0.39) Est; Revenue of \$3.42M vs \$2.60M Est

Financial news for ANAC dated on 2013-07-29: Anacor Pharma Submits NDA for Tavaborole

Financial news for ANAC dated on 2013-07-18: Anacor Pharmaceuticals to Present Pivotal Phase 3 Data of Tavaborole for the Topical Treatment of Toenail Onychomycosis

Financial news for ANAC dated on 2013-07-18: Anacor Pharmaceuticals to Present Phase 3 Data of Tavaborole for the Topical Treatment of Toenail Onychomycosis

Financial news for ANAC dated on 2013-06-12: Anacor Pharmaceuticals Secures \$45M Loan Facility

Financial news for ANAC dated on 2013-05-09: Anacor Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.42) vs \$(0.39) Est; Revenue of \$1.71M vs \$2.57M Est

Financial news for ANAC dated on 2013-05-02: Valeant Pharmaceuticals Agrees to Delay Efinconazole Launch

Financial news for ANAC dated on 2013-05-02: Anacor Issues Update on Arbitration with Valeant, Says Prelim. Injunction Hearing Cancelled

Financial news for ANAC dated on 2013-05-01: Anacor Pharmaceuticals Announces Closing of \$23M Public Offering of Common Stock, Including Full Exercise of Underwriters' Over-Allotment Option

Financial news for ANAC dated on 2013-04-26: Anacor Pharma Prices 3.13M Shares at \$6.39/Share

Financial news for ANAC dated on 2013-04-25: Anacor Pharma Files to Offer Shares of Stock

Financial news for ANAC dated on 2013-04-09: Benzinga's Top Pre-Market Gainers

Financial news for ANAC dated on 2013-04-08: Anacor Pharma Receives \$17.7M Investment from Gates Foundation

Financial news for ANAC dated on 2013-03-23: Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)

Financial news for ANAC dated on 2013-03-22: Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus

Financial news for ANAC dated on 2013-03-22: Benzinga's Top Pre-Market Gainers

Financial news for ANAC dated on 2013-03-21: Wedbush Maintains Outperform on Anacor Pharmaceuticals, Inc., Raises PT to \$20.00

Financial news for ANAC dated on 2013-03-21: A Peek Into The Market Before The Trading Starts

Financial news for ANAC dated on 2013-03-21: Anacor Announces Positive Phase 2 Dose-Results for AN2728 in Adolescents With Atopic Dermatitis

Financial news for ANAC dated on 2013-03-14: Anacor Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.36) vs \$(0.44) Est; Revenue of \$3.29M vs \$3.25M Est

Financial news for ANAC dated on 2013-03-14: Earnings Scheduled For March 14, 2013

Financial news for ANAC dated on 2013-02-28: Anacor Pharmaceuticals Announces Positive Results from the Second Phase 3 Trial of Tavaborole for Onychomycosis

Financial news for ANAC dated on 2013-02-11: Stocks Hitting 52-Week Lows

Financial news for ANAC dated on 2013-01-30: UPDATE: Canaccord Genuity Reiterates Buy Rating, Lowers PT on Anacor Pharmaceuticals

Financial news for ANAC dated on 2013-01-30: Canaccord Genuity Maintains Buy on Anacor Pharmaceuticals, Inc., Lowers PT to \$5.00

Financial news for ANAC dated on 2013-01-29: Stocks Hitting 52-Week Lows

Financial news for ANAC dated on 2013-01-29: A Peek Into The Market Before The Trading Starts

Financial news for ANAC dated on 2013-01-29: Anacor Pharmaceuticals Announces

Positive Phase 3 Trial Results for Tavaborole for Onychomycosis

Financial news for ANAC dated on 2012-12-10: Anacor Pharmaceuticals Announces Positive Results From Phase 2 Trial of AN2728

Financial news for ANAC dated on 2012-12-04: Capstone Initiates Coverage on Anacor Pharmaceuticals, Inc. at Buy, Announces \$8.00 PT

Financial news for ANAC dated on 2012-12-04: From Earlier: Capstone Initiates Coverage on Anacor Pharmaceuticals, Inc. at Buy, Announces \$8.00 PT

Financial news for ANAC dated on 2012-11-07: UPDATE: Anacor Pharmaceuticals Reports Q3 EPS \$-0.46 vs \$-0.45 Est; Revenues \$2.5M vs \$3.18M Est

Financial news for ANAC dated on 2012-11-07: Anacor Pharmaceuticals Reports Q3 Revenues \$2.5M vs \$3.18M Est

Financial news for ANAC dated on 2012-10-18: Anacor Pharmaceuticals Prices \$24 Million Public Offering of Common Stock

Financial news for ANAC dated on 2012-10-17: Anacor Pharmaceuticals Announces Proposed Public Offering of Common Stock

Financial news for ANAC dated on 2012-10-05: Anacor Pharmaceuticals Announces That GSK Has Discontinued Clinical Development of GSK2251052

Financial news for ANAC dated on 2012-08-09: Anacor Pharmaceuticals Reports Q2 EPS \$-0.47 vs \$-0.45 Est; Revenues \$2.56M vs \$3.11M Est

Financial news for ANAC dated on 2012-07-13: 3 New Bets by a Biotech Hedge Fund

Financial news for ANAC dated on 2012-06-05: Canaccord Assumes Anacor Pharmaceuticals at Buy, \$8 PT

Financial news for ANAC dated on 2012-06-01: Anacor Pharmaceuticals Appoints Paul L. Berns to Its Board of Directors

Financial news for ANAC dated on 2012-03-13: Earnings Scheduled For March 13

Financial news for ANAC dated on 2012-03-12: Anacor Pharmaceuticals Announces Commencement of Phase 1 Clinical Trials of Boron-Based Compound for Sleeping Sickness

Financial news for ANAC dated on 2012-03-05: Earnings Scheduled For March 5

Financial news for ANAC dated on 2012-02-08: Anacor Pharmaceuticals Announces the Sale of 3.25 Million Shares of Common Stock

Financial news for ANAC dated on 2012-02-07: Anacor Pharmaceuticals Announces Positive Preliminary Results from Two Safety Studies of AN2728 and Updates Atopic Dermatitis Results and Regulatory Status

Financial news for ANAC dated on 2012-02-06: Anacor Pharma Analyst: We Remain Buyers of Shares Based on Positive View of 4 Mid to Late Stage Novel Oxaborole Compounds Positioned to Address Large Anti-Infective Markets

Financial news for ANAC dated on 2012-02-06: Anacor Pharmaceuticals Down 14.4% After GlaxoSmithKline Pauses Ongoing Trials

Financial news for ANAC dated on 2012-02-06: Anacor Pharmaceuticals Resumes Trading

Financial news for ANAC dated on 2012-02-06: PREVIEW: Anacor Pharmaceuticals to Resume Trading at 9:00am

Financial news for ANAC dated on 2012-02-06: Anacor Pharmaceuticals Announces That Its Partner GSK Has Voluntarily Paused Enrollment of Ongoing GSK '052 Phase 1 and 2

Financial news for ANAC dated on 2012-02-06: Trading Halted in Anacor Pharma, News Pending

Financial news for ANAC dated on 2011-12-28: Stocks To Watch For December 28

Financial news for ANAC dated on 2011-12-27: Anacor Pharma Registers To Offer Up To \$50M In Mixed Securities

Financial news for ANAC dated on 2011-12-22: Anacor Pharmaceuticals Completes Enrollment in Second of Two Phase 3 Trials of Tavaborole for Onychomycosis

Financial news for ANAC dated on 2011-12-13: Wedbush Maintains Outperform, \$13 Target on Anacor

Financial news for ANAC dated on 2011-12-12: Anacor Pharmaceuticals Announces Positive Preliminary Results from Phase 2a Trial of AN2728 and AN2898 in Atopic Dermatitis

Financial news for ANAC dated on 2011-12-12: Anacor Pharmaceuticals Announces Positive Preliminary Results from Phase 2a Trial of AN2728 and AN2898 in Atopic Dermatitis

Financial news for ANAC dated on 2011-11-14: Investor Ideas' Friday's NASDAQ Winners

Financial news for ANAC dated on 2011-11-10: Anacor Pharmaceuticals, Inc. Reports Q3 Revenues \$12.6M vs \$5.58M Est

Financial news for ANAC dated on 2011-11-09: Anacor Pharmaceuticals Completes Enrollment in First of Two Phase 3 Trials of AN2690 for Onychomycosis

Financial news for ANAC dated on 2011-09-07: Anacor's Partner GlaxoSmithKline Awarded up to \$94 Million in U.S. Government Funding to Support Development of GSK '052

Financial news for ANAC dated on 2011-08-31: Anacor Pharmaceuticals and Medicines for Malaria Venture Extend Development Agreement for AN3661 for the Treatment of Malaria

Financial news for ANAC dated on 2011-08-11: Anacor Pharmaceuticals Reports Q2 EPS \$(0.54) vs \$(0.45) Est; Revenues \$2.9M vs \$4M Est

Financial news for ANAC dated on 2011-08-10: Tuesday's Top Performing Small Cap Stocks (PNX, ANAC, FRP, NOG, MAKO)

Financial news for ANAC dated on 2011-08-10: Tuesday's Top Performing Small Cap Stocks (PNX, ANAC, FRP, NOG, MAKO)

Financial news for ANAC dated on 2011-08-09: Morning Market Movers

Financial news for ANAC dated on 2011-08-08: Anacor Pharma Resumes Trading

Financial news for ANAC dated on 2011-08-08: Anacor Pharma Halted, Circuit Breaker

Financial news for ANAC dated on 2011-06-29: Wedbush Reiterates Outperform and PT of \$13 on Anacor Pharmaceuticals

Financial news for ANAC dated on 2011-06-28: Anacor Pharmaceuticals Partnership Advances Novel Drug Candidate to Combat Sleeping Sickness

Financial news for ANAC dated on 2011-06-27: Anacor Pharmaceuticals Announces Positive Preliminary Results from Phase 2b Trial of AN2728 for Psoriasis

Financial news for ANAC dated on 2011-06-22: Anacor Pharmaceuticals Announces GSK Has Initiated Two Phase 2 Trials of GSK '052 in Complicated Urinary Tract Infections and Complicated Intra-Abdominal Infections

Financial news for ANAC dated on 2011-04-07: Deutsche Bank Maintains Buy Rating On ANAC

Financial news for ANAC dated on 2011-03-17: Anacor Pharmaceuticals Announces Development Agreement with Medicines for Malaria Venture

Financial news for ANAC dated on 2011-03-14: Anacor Pharmaceuticals Completes Enrollment in Phase 2b Trial of AN2728 for Psoriasis

Financial news for ANAC dated on 2011-03-10: Anacor Pharmaceuticals Reports 2010 Q4r and Year End Financial Results (ANAC)

Financial news for ANAC dated on 2011-03-07: Anacor Pharmaceuticals Launches Research Collaboration with the Institute for OneWorld Health

Financial news for ANAC dated on 2011-02-04: Anacor Pharmaceuticals Announces First Patient Dosed in a Phase 2b Trial of AN2728

Financial news for ANAC dated on 2011-01-07: Wedbush Initiates Anacor Pharmaceuticals Coverage, Shares Climb 13.3% To 52-Week High (ANAC)

Financial news for ANAC dated on 2011-01-04: Anacor Pharmaceuticals Up 8.8% To 52-Week High (ANAC)

Financial news for ANAC dated on 2011-01-03: Anacor Pharmaceuticals Climbs 11.6% (ANAC)

Financial news for ANAC dated on 2011-01-03: Deutsche Bank Opens ANAC With Buy

Financial news for ANAC dated on 2010-12-23: Anacor Pharmaceuticals Announces Exercise of Over-Allotment Option for Recent Initial Public Offering

Financial news for ANAC dated on 2010-12-02: Anacor Pharmaceuticals Director Buys 600,000 Shares of ANAC

Financial news for ANAC dated on 2010-11-30: Anacor Pharmaceuticals Completes \$70M IPO

Financial news for ANAC dated on 2010-11-24: A Peek Into The Market Before The Trading Starts

Financial news for ANAC dated on 2010-11-24: Anacor Pharmaceuticals Prices Its IPO at \$5.00 per Share